The addition of a DPP-4 inhibitor decreased HbA1C while not requiring an increase in insulin, and subjects remained weight neutral without experiencing an increase in hypoglycemic events… Currently approved dipeptidyl peptidase-4 (DPP-4) inhibitors include alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin. DPP-4 inhibitors work by enhancing glucose dependent insulin secretion and …
Read More »Metformin Is Best Initial Oral Drug for Lowering Glucose Levels in Diabetes Patients
Metformin, sulfonylureas, thiazolidinedione, and DPP-4 inhibitors were compared to evaluate the effects on the time to subsequent treatment… There are many classes of oral drugs used for diabetes therapy, but there is a lack of evidence as to which drug is best for use as initial therapy. Most patients diagnosed …
Read More »Exenatide a Noninsulin Addition for Patients Failing Basal Insulin
Exenatide twice daily shows similar glycemic control with weight loss and less hypoglycemia as compared to mealtime insulin… Some patients with advanced type 2 diabetes still do not achieve glycemic control with insulin glargine and metformin. Mealtime insulin lispro is often added on to the regimen but it is associated …
Read More »Light Technology May Be Used to Control Type 2 Diabetes
Use of blue LED light activates sulfonylureas… The use of sulfonylureas has long been an option for controlling type 2 diabetes. Their use is often associated with hypoglycemia and weight gain. A new technology seeks to minimize these side effects. Researchers are looking at a prototype sulfonylurea, JB253, which stimulates …
Read More »GLP-1 Receptor Agonist a Treatment Option in Type 2 Patients with Renal Insufficiency
Phase 3 trial demonstrates the safety and efficacy of albiglutide in type 2 diabetes patients with renal impairment…. Renal impairment is a common comorbid condition in type 2 diabetes patients with reported incidence rates as high as 35%. Those with renal insufficiency often find their diabetes treatment options limited. Possible …
Read More »Liraglutide (Victoza) Provides Good Control with Less Hypoglycemia for MODY
Besides sulfonylureas, GLP-1RA can also be a treatment option for HNF1A diabetic patients…. Maturity-onset diabetes of the young adults (MODY) is responsible for 1-2% of all cases of diabetes. HNF1A diabetes is caused by loss of B-cell functions. It is usually misclassified as type 1 diabetes due to common hyperglycemic …
Read More »Stanley Schwartz, MD, FACP, FACE: Introduction, ADA 2014
Dr. Stanley Schwartz introduces himself briefly and talks about how much he enjoying his “working retirement” and actually get more academic work done since he left academia. He also says that he is “having great fun taking care of my patients and advacning the ideas I come up with as …
Read More »Stanley Schwartz, MD: A New Way of Classifying Diabetes – The Beta-Cell Centric Approach
Dr. Stanley Schwartz talks about his groundbreaking presentation at the 2014 ADA in which he outlined a new approach to classifying diabetes based on the health of the patient’s beta-cells. He explains in detail here how the current system of classification is full of contradictions and overlap between different types …
Read More »Stanley Schwartz, MD: Picking the Right Drugs for the Right Patients
Dr. Stanley Schwartz talks about choosing the right drugs for each individual patient, and which ones should be first tier choices, which ones second, and the efficacy we should be looking for from them…. More videos in this series with Dr. Schwartz Stanley Schwartz, MD, FACP, FACE: Introduction, ADA …
Read More »Stanley Schwartz, MD: Positive Effects of More Aggressive Treatment
Dr. Stanley Schwartz relates his overwhelmingly positive experience treating patients with newer drug therapies such as GLP-1 agonists and SGLT-2 inhibitors. He explains that he will sometimes put patients, on the very first day of their visit, on these medications when their A1c’s are very high and, one month later, …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.